1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Pilot Projects Investigating Understudied Proteins Associated with Rare Diseases (R03 Clinical Trial Not Allowed) is sponsored by National Center for Advancing Translational Sciences (NCATS)/National Institutes of Health (NIH). This R03 grant supports pilot projects that investigate understudied proteins associated with rare diseases.
Leukodystrophies are rare diseases, and research into the proteins involved in their pathogenesis would be highly relevant.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Academic and research institutions are typically eligible for NIH R03 grants. This program supports early-stage research. Confirm the full requirements in the official notice before applying.
Applications for Pilot Projects Investigating Understudied Proteins Associated with Rare Diseases (R03 Clinical Trial Not Allowed) are due October 16, 2026. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
Pilot Projects Investigating Understudied Proteins Associated with Rare Diseases (R03 Clinical Trial Not Allowed) is funded by National Center for Advancing Translational Sciences (NCATS)/National Institutes of Health (NIH). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
Advance from NIH SBIR Phase I to Phase II with tips on demonstrating feasibility, building a commercialization plan, and securing $1M in funding.
Read articlePAR-27-056 replaces the long-running IDeA-CTR U54 cooperative agreement with a P30 center core grant and splits the program into Development and Network tracks. Posted August 19, 2026, with a first estimated due date of October 9. Here is what the mechanism swap actually changes for the 23 IDeA states and Puerto Rico.
Read articleThe U.S. Government Policy for Stopping High-Risk Life Sciences Research, released July 28, 2026 under EO 14292 and implemented at NIH through NOT-OD-26-101, replaces mitigation with prohibition. It bans dangerous gain-of-function research outright, gates potential DGOF behind government-wide review, and creates International Research of Concern — a research-security regime wearing biosafety clothing. Penalties run to five-year debarment and False Claims Act exposure.
Read article